Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1997 Sep;12(9):567-80.
doi: 10.1046/j.1525-1497.1997.07111.x.

Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practice

S Vijan  1 , D L Stevens, W H Herman, M M Funnell, C J Standiford
Affiliations
Review

Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practice

S Vijan et al. J Gen Intern Med. 1997 Sep.

Abstract

Purpose: To summarise current knowledge of interventions that should improve the care of patients with type II diabetes mellitus. Interventions lie within the realms of preventions, screening, and treatment, all of which are focused on office practice.

Methods: Review of the literature by a multidisciplinary team involved in the care of patients with diabetes, followed by synthesis of the literature into a clinical care guideline. Literature was identified through consultation with experts and a focused MEDLINE search.

Main results: An algorithm-based guideline for screening and treatment of the complications of diabetes was developed. The emphasis is on prevention of atherosclerotic disease, and prevention, screening, and early treatment of microvascular disease. Implementation of these practices has the potential to significantly improve quality of life and increase life expectancy in patients with type II diabetes mellitus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Screening, prevention, and treatment of cardiovascular risk factors in patients with type II diabetes mellitus: hypertension, hyperlipidemia, and smoking.
Figure 2
Figure 2
Screening, prevention, and treatment of microvascular complications in patients with type II diabetes mellitus: retinopathy, nephropathy, and neuropathy.
Figure 3
Figure 3
Monitoring glycemic control in patients with type II diabetes mellitus.
Figure 4
Figure 4
How to use the monofilament. (Source: The Gillis W. Long Hansen’s Disease Center, Carville, La., and Dr. Charles Patout, Jr. This is a public document. The center is no longer in existence.)
See this image and copyright information in PMC

Comment in

  • ACP J Club. 1998 Mar-Apr;128(2):30

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. National Diabetes Data Group. 2nd ed. Bethesda, Md: National Institutes of Health; 1995. Diabetes in America.
    1. Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med. 1996;125:221–32. - PubMed
    1. The Diabetes Control and Complications Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276:1409–15. - PubMed
    1. Krolewski AS, Czyczyk A, Janeczko D, Kopczynski J. Mortality from cardiovascular diseases among diabetics. Diabetologia. 1977;13:345–50. - PubMed
    1. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:123–31. Published erratum appears in Diabetologia. 1987;30:364. - PubMed

MeSH terms